Midas Database for Drug Pricing and Utilization, including Disease and Patient functionality

The Patented Medicine Prices Review Board (PMPRB) is seeking to acquire a fully developed database that compiles comprehensive drug utilization data for both the retail and hospital sectors. This database must contain detailed information on pricing at various stages—including ex-factory, wholesale, and retail levels—in local and US currencies, along with quantities and revenues of medicines sold across Canada and all OECD countries. The data must be gathered impartially and thoroughly through surveys of hospitals, pharmacies, and wholesalers, ensuring a complete and unbiased view of the pharmaceutical market. This resource is essential for the PMPRB’s role in monitoring and evaluating patented medicine prices to protect consumers from excessive pricing and to inform policy decisions. The database, titled "Midas Database for Drug Pricing and Utilization, including Disease and Patient functionality," supports the PMPRB's mandate by providing critical market insights and international price comparisons. The information obtained from this database not only aids in hearings and enforcement actions related to patent abuse but also contributes to ongoing research into pharmaceutical trends, sales, pricing, and research and development expenditures. The contract, open from April 8 to April 23, 2026, will be managed out of Ottawa and points to a requirement for neutral and timely analytical support requested by government officials. The PMPRB relies on this data to maintain transparency and evidence-based regulation within the biopharmaceutical ecosystem in Canada and internationally.